Zetar
ADDBuy-and-build confectionary and snacks group Zetar has churned out sweet results for the year to April and an acquisition since the year-end provides investors with even more to chew over.
Already becoming established as a leading niche producer of white-label chocolate products for UK supermarkets through its Kinnerton division, Zetar is in an excellent position to capitalise on the ever-increasing consumer interest in ‘healthier’ eating.
Last year the group expanded the confectionary division’s premium end with the acquisition of Salamander, a producer of fruit and nuts ‘enrobed’ in such coverings as Fair Trade chocolate or yoghurt. At its natural snacks division, Zetar also added organic dried fruit importer Humdinger to its existing fruit and nut business. Both arrivals have extended their product ranges and developed new products and will be beneficiaries of some of the £3m investment this year.
The post year-end acquisition of Britannia opened the door to the fast-growing, health-driven baked snacks and biscuits sector. Zetar’s chief executive Ian Blackburn says trading at loss-making Britannia should be much improved by Zetar’s ability to increase sales, but he admits it will ‘hold earnings back this year’.
Although Britannia will dominate in terms of management time this year, Blackburn has considerably strengthened the board to help push through the many plans to boost sales and increase synergies between divisions.
A barnstorming start has been made in the new year, with sales for the first 11 weeks of £12.4m versus the £7.1m last time. This has led independent broker Altium to upgrade 2008 forecasts to £7.2m pre-tax profit and 41.8p of earnings. Recommended by GCI at 335p in February last year, the shares have run out of steam a little of late but, considering the likely organic and acquisitive growth, we feel there is more to come. Add.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £61.22m
PE Forecast: 13.6
Share price: 570p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
